` IIQ (INOVIQ Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

IIQ
vs
S
S&P/ASX 300

Over the past 12 months, IIQ has underperformed S&P/ASX 300, delivering a return of -35% compared to the S&P/ASX 300's +7% growth.

Stocks Performance
IIQ vs S&P/ASX 300

Loading
IIQ
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
IIQ vs S&P/ASX 300

Loading
IIQ
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
IIQ vs S&P/ASX 300

Loading
IIQ
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
INOVIQ Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

INOVIQ Ltd
Glance View

Market Cap
49.3m AUD
Industry
Health Care

INOVIQ Ltd. is a biotechnology company, which engages in the provision of medical services. The firm is focused on developing and commercializing a portfolio of diagnostic and exosome-based solutions to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Company’s products include hTERT ICC test, which is an immunocytochemistry (ICC) assay that detects hTERT and is used as an adjunct to urine cytology, and EXO-NET RUO, which is a pan-exosome capture tool for isolation of exosomes from body fluids including plasma, urine, and saliva. The company is also developing solutions using SubB2M, NETs, BARD1 and hTERT technologies to improve patient health outcomes.

IIQ Intrinsic Value
0.11 AUD
Overvaluation 68%
Intrinsic Value
Price
Back to Top